These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 26191134)

  • 1. Alterations in ubiquitin ligase Siah-2 and its corepressor N-CoR after P-MAPA immunotherapy and anti-androgen therapy: new therapeutic opportunities for non-muscle invasive bladder cancer.
    Garcia PV; Apolinário LM; Böckelmann PK; da Silva Nunes I; Duran N; Fávaro WJ
    Int J Clin Exp Pathol; 2015; 8(5):4427-43. PubMed ID: 26191134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased toll-like receptors and p53 levels regulate apoptosis and angiogenesis in non-muscle invasive bladder cancer: mechanism of action of P-MAPA biological response modifier.
    Garcia PV; Seiva FR; Carniato AP; de Mello Júnior W; Duran N; Macedo AM; de Oliveira AG; Romih R; Nunes Ida S; Nunes Oda S; Fávaro WJ
    BMC Cancer; 2016 Jul; 16():422. PubMed ID: 27389279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of intravesical instillation of a novel biological response modifier (P-MAPA) on progress of non-muscle invasive bladder cancer treatment in a rat model.
    Fávaro WJ; Socca EAR; Böckelmann PK; Reis IB; Garcia PV; Durán N
    Med Oncol; 2022 Jan; 39(2):24. PubMed ID: 34982270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P-MAPA immunotherapy potentiates the effect of cisplatin on serous ovarian carcinoma through targeting TLR4 signaling.
    de Almeida Chuffa LG; de Moura Ferreira G; Lupi LA; da Silva Nunes I; Fávaro WJ
    J Ovarian Res; 2018 Jan; 11(1):8. PubMed ID: 29343281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential therapeutic strategies for non - muscle invasive bladder cancer based on association of intravesical immunotherapy with p - mapa and systemic administration of cisplatin and doxorubicin.
    Dias QC; Nunes ID; Garcia PV; Favaro WJ
    Int Braz J Urol; 2016; 42(5):942-954. PubMed ID: 24893914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of intravesical therapy with platelet-rich plasma (PRP) and Bacillus Calmette-Guérin (BCG) in non-muscle invasive bladder cancer.
    Dias LP; Luzo ÂCM; Volpe BB; Durán M; Galdames SEM; Ferreira LAB; Durán N; Fávaro WJ
    Tissue Cell; 2018 Jun; 52():17-27. PubMed ID: 29857824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen Receptor Signaling Reduces the Efficacy of Bacillus Calmette-Guérin Therapy for Bladder Cancer via Modulating Rab27b-Induced Exocytosis.
    Mizushima T; Jiang G; Kawahara T; Li P; Han B; Inoue S; Ide H; Kato I; Jalalizadeh M; Miyagi E; Fukuda M; Reis LO; Miyamoto H
    Mol Cancer Ther; 2020 Sep; 19(9):1930-1942. PubMed ID: 32737155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen receptor activation: a prospective therapeutic target for bladder cancer?
    Mizushima T; Tirador KA; Miyamoto H
    Expert Opin Ther Targets; 2017 Mar; 21(3):249-257. PubMed ID: 28064545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravesical Thalidomide boosts bacillus Calmette-Guérin (BCG) in non-muscle invasive bladder cancer treatment.
    Passos GR; Camargo JA; Ferrari KL; Saad MJA; de Mattos AC; Reis LO
    Med Oncol; 2017 Dec; 35(1):3. PubMed ID: 29209984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer.
    Lamm D; Brausi M; O'Donnell MA; Witjes JA
    Urol Oncol; 2014 Jan; 32(1):35.e21-30. PubMed ID: 23628309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiandrogen Therapy with Hydroxyflutamide or Androgen Receptor Degradation Enhancer ASC-J9 Enhances BCG Efficacy to Better Suppress Bladder Cancer Progression.
    Shang Z; Li Y; Zhang M; Tian J; Han R; Shyr CR; Messing E; Yeh S; Niu Y; Chang C
    Mol Cancer Ther; 2015 Nov; 14(11):2586-94. PubMed ID: 26264279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravesical bacillus Calmette-Guerin immunotherapy after previous prostate radiotherapy for high-grade non-muscle-invasive bladder cancer.
    Rao MV; Ellimoottil C; Sondej T; Flanigan RC; Quek ML
    Urol Oncol; 2013 Aug; 31(6):857-61. PubMed ID: 21868262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P-MAPA and Interleukin-12 Reduce Cell Migration/Invasion and Attenuate the Toll-Like Receptor-Mediated Inflammatory Response in Ovarian Cancer SKOV-3 Cells: A Preliminary Study.
    Lupi LA; Delella FK; Cucielo MS; Romagnoli GG; Kaneno R; Nunes IDS; Domeniconi RF; Martinez M; Martinez FE; Fávaro WJ; Chuffa LGA
    Molecules; 2019 Dec; 25(1):. PubMed ID: 31861351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder.
    Miyamoto H; Yao JL; Chaux A; Zheng Y; Hsu I; Izumi K; Chang C; Messing EM; Netto GJ; Yeh S
    BJU Int; 2012 Jun; 109(11):1716-26. PubMed ID: 22221549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A molecular complex of bovine milk protein and oleic acid selectively kills cancer cells in vitro and inhibits tumour growth in an orthotopic rat bladder tumour model.
    Xiao Z; Mak A; Koch K; Moore RB
    BJU Int; 2013 Jul; 112(2):E201-10. PubMed ID: 23356235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toll-like receptors: The role in bladder cancer development, progression and immunotherapy.
    Ohadian Moghadam S; Nowroozi MR
    Scand J Immunol; 2019 Dec; 90(6):e12818. PubMed ID: 31448424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ELK1 is up-regulated by androgen in bladder cancer cells and promotes tumor progression.
    Kawahara T; Shareef HK; Aljarah AK; Ide H; Li Y; Kashiwagi E; Netto GJ; Zheng Y; Miyamoto H
    Oncotarget; 2015 Oct; 6(30):29860-76. PubMed ID: 26342199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reported use of intravesical therapy for non-muscle-invasive bladder cancer (NMIBC): results from the Bladder Cancer Advocacy Network (BCAN) survey.
    Nielsen ME; Smith AB; Pruthi RS; Guzzo TJ; Amiel G; Shore N; Lotan Y
    BJU Int; 2012 Oct; 110(7):967-72. PubMed ID: 22487336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of combined intravesical immunotherapy and chemotherapy for non-muscle invasive bladder cancer.
    Hilton WM; Ercole B; Parekh DJ; Sonpavde G; Ghosh R; Svatek RS
    Expert Rev Anticancer Ther; 2011 Jun; 11(6):949-57. PubMed ID: 21707292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of androgen receptor and Cdc25A phosphatase as a combination targeted therapy in molecular apocrine breast cancer.
    Naderi A; Liu J
    Cancer Lett; 2010 Dec; 298(1):74-87. PubMed ID: 20605569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.